Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients
- 7 June 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in Angiogenesis
- Vol. 9 (2), 73-81
- https://doi.org/10.1007/s10456-006-9033-1
Abstract
Vascular endothelial growth inhibitor (VEGI) is a novel anti-angiogenic cytokine that belongs to the tumour necrosis factor (TNF) superfamily. Very little is known about the significance of VEGI in cancer. Our study analysed VEGI expression in relation to breast cancer patient clinical parameters. The VEGI expression profile was assessed qualitatively (RT-PCR), quantitatively (real-time Quantitative-PCR), and immuno-histochemically (IHC), in a panel of 24 human normal and cancer cell lines and in a cohort of 151 mammary tissue samples (n = 33 normal breast tissue; n = 118 breast cancer tissue) with a 6-year median follow-up. Patients who had died of breast cancer or had local recurrence of the disease expressed significantly lower levels of VEGI in comparison to the elevated levels in the disease free patients. High levels of VEGI were associated with an increased chance of patient survival. Importantly, patients with breast tumours expressing reduced levels of VEGI had a poorer prognosis than those patients expressing high levels of VEGI. However, no significant correlations were observed between VEGI expression and tumour grade, TNM classification, or nodal involvement. In conclusion, VEGI is aberrantly expressed in human breast cancer tissues. VEGI displays prognostic relevance as breast cancer patients with an overall poor prognosis express significantly lower levels of VEGI compared to those with a favourable prognosis.Keywords
This publication has 35 references indexed in Scilit:
- VEGI-192, a New Isoform of TNFSF15, Specifically Eliminates Tumor Vascular Endothelial Cells and Suppresses Tumor GrowthClinical Cancer Research, 2005
- Characterization of cis-regulatory elements of the vascular endothelial growth inhibitor gene promoterBiochemical Journal, 2005
- The Hepatocyte Growth Factor Regulatory Factors in Human Breast CancerClinical Cancer Research, 2004
- TL1A Is a TNF-like Ligand for DR3 and TR6/DcR3 and Functions as a T Cell CostimulatorImmunity, 2002
- A novel secreted splice variant of vascular endothelial cell growth inhibitorThe FASEB Journal, 2002
- Clinical significance of the determination of angiogenesis in human breast cancer: Update of the biological background and overview of the vicenza studiesEuropean Journal of Cancer, 1996
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Enhancement of Tumor Growth and Vascular Density by Transfection of Vascular Endothelial Cell Growth Factor Into MCF-7 Human Breast Carcinoma CellsJNCI Journal of the National Cancer Institute, 1995
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990
- The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity.The Journal of Experimental Medicine, 1988